SEPTIN9基因甲基化在消化系统肿瘤研究及临床诊治中的价值

表1 不同指标用于诊断的灵敏度及特异度

肿瘤类型	指标(灵敏度, 特异度)	参考文献
结直肠癌	SEPTIN9(75%, 91%) vs CEA(39%, 89%) vs CA199(16%, 96%) vs CA724(18%, 82%)	[20]
	SEPTIN9(73.3%, 81.5%) vs FIT(68.0%, 97.4%)	[22]
	CEA(51.0%, 75.4%) vs CA199(16.4%, 94.6%) vs FIT(66.4%, 84.6%) vs SEPTIN9(83.7%, 94.6%) vs SDC2(76.9%, 90.8%) vs BCAT1(83.7%, 93.9%) vs SEPTIN9+SDC2+BCAT1(82.7%, 96.9%)	[25]
	SEPTIN9+SDC2+VIM(81.8%)	[26]
	CEA+CA199+CA125+CA724(60.3%, 86.4%) vs FOBT(62.1%, 88.6%) vs SEPTIN9(55.2%, 97.7%) vs SDC2(73.3%, 97.7%) vs SEPTIN9+SDC2(86.2%, 95.5%)	[27]
	CEA(50.6%, 89.9%) vs SEPTIN9(69.5%, 88.1%) vs SEPTIN9+CEA(75.1%, 86.8%) vs SEPTIN9+LMR(82.3%, 84.6%) vs SEPTIN9+LMR+CEA(82.7%, 84.1%)	[28]
	SEPTIN9(61.8%, 89.6%) vs FOBT(61.4%, 70.3%) vs SEPTIN9+FOBT(84.1%, 62.2%)	[29]
	SEPTIN9(66.7%, 59.2%) vs IGFBP2(67.2%, 66.9%) vs DKK3(58.5%, 58.1%) vs PKM2(49.2%, 49.2%) vs SEPTIN9+IGFBP2+DKK3+PKM2(67.8%, 67.8%) vs SEPTIN9+IGFBP2+DKK3(56.6%, 73.3%) vs SEPTIN9+IGFBP2(42.6%, 87.5%)	[30]
肝癌	SEPTIN9(82.7%, 96.0%) vs AFP(57.7%, 98.3%) vs SEPTIN9+AFP(91.3%, 87.7% )	[38]
	SEPTIN9(65.31%, 92.86%) vs AFP(44.24%, 89.26%) vs PIVKA-Ⅱ(62.22%, 95.27%) vs SEPTIN9+AFP+PIVKA-Ⅱ(84.00%, 85.57%)	[39]
胆管癌	SEPTIN9(28.21%, 96.94%) vs HOXA9(51.92%, 96.94%) vs SHOX2(23.72%, 97.96 %) vs RASSF1A(29.49%, 97.96%) vs CA199(51.28%, 87.76%)SEPTIN9+HOXA9+SHOX2+RASSF1A(64.74%, 93.88%)	[41]
胃癌	SEPTIN9(40.0%, 96.0%) vs RNF180(40.0%, 96.0%) vs SEPTIN9+RNF180(62.2%, 84.8%)	[43]
	SEPTIN9(35.00%, 100.00%) vs SEPTIN9+CEA+CA199+CA724+CA125(66.25%, 96.77%)	[45]
食管癌	鳞癌: SHOX2+SEPTIN9+RNF180+EPO(77.40%, 85.29%) vs SCCA(28.81%, 90.20%); 腺癌: SHOX2+SEPTIN9+RNF180+EPO(66.67%, 86.27%) vs CA199(18.18%, 87.25%) vs CEA(21.21%, 86.27%)	[46]
	SEPTIN9(43.1%, 95.6%) vs SNCG 41.8%, 92.6%) vs SEPTIN9+SNCG(71.8%, 90.3%)	[47]
	SEPTIN9+TFPI2+FHIT(79.8%, 95.0%)	[48]

FIT: 免疫法粪便潜血试验; FOBT: 粪便潜血试验; CEA: 癌胚抗原; CA199:糖类抗原199; LMR: 淋巴细胞与单核细胞比; IGFBP2: 血清蛋白胰岛素样生长因子结合蛋白2; DKK3: Dickkopf相关蛋白3; PKM2-丙酮酸激酶M2; AFP: 甲胎蛋白; PIVKA-Ⅱ: 异常凝血酶原; SCCA: 鳞状细胞癌抗原; SNCG: 突触核蛋白γ; TFPI2: 组织因子途径抑制物2; FHIT: 脆性组氨酸三联体基因.